uniQure N.V. has submitted a Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval of ifezuntirgene inilparvovec, previously known as AMT-130, for Huntington’s disease. The company has simultaneously submitted a Marketing Authorisation Application to the U.K. Medicines and Healthcare products Regulatory Agency, creating parallel regulatory reviews for a one-time gene therapy that is designed to lower production of the toxic huntingtin protein responsible for the inherited neurodegenerative disease. uniQure has requested Priority Review in the United States, which, if granted after the FDA’s initial filing review, would shorten the formal review period to approximately six months.
The filing is unusually consequential because there are currently no approved therapies demonstrated to slow the underlying progression of Huntington’s disease. Drugs can help manage chorea and selected psychiatric or behavioral symptoms, but they do not modify the genetic process that progressively damages neurons. uniQure’s application therefore asks regulators to consider whether data from a relatively small gene-therapy program, benchmarked in part against a carefully matched natural-history cohort, are sufficiently persuasive to support accelerated approval before a conventional large randomized outcomes trial is completed.
What did the three-year AMT-130 data actually show?
The pivotal three-year analysis focused heavily on patients receiving the high dose of AMT-130 and compared their outcomes with propensity-score-matched participants from the Enroll-HD natural-history database. High-dose patients showed a 0.38-point mean decline from baseline on the composite Unified Huntington’s Disease Rating Scale, compared with a 1.52-point decline among the matched external controls. uniQure calculated that difference as a statistically significant 75% slowing of disease progression, with a p-value of 0.003.
Total Functional Capacity provided another important signal because it measures how well people retain abilities needed for work, finances, domestic responsibilities and daily living. High-dose AMT-130 patients showed a mean 0.36-point decline compared with 0.88 points in the matched control population, corresponding to a statistically significant 60% slowing of functional decline. Additional motor and cognitive measures generally moved in a favorable direction, while cerebrospinal-fluid neurofilament light levels at three years were also reported below baseline in the high-dose group.
These numbers explain why the filing has generated so much attention, but they also expose the central regulatory debate. The pivotal comparison does not come from hundreds of patients randomized contemporaneously between gene therapy and placebo. Instead, uniQure is asking the FDA to accept a smaller treated population compared with an external control constructed from natural-history data, an approach that can be particularly useful in rare progressive diseases but requires regulators to be convinced that the groups are sufficiently comparable.
Why did uniQure use an external control instead of a conventional Phase 3 trial?
AMT-130 is administered through MRI-guided stereotactic neurosurgery directly into the striatum, including the caudate and putamen. Creating a conventional placebo-controlled pivotal trial could therefore require patients in the control arm to undergo an invasive sham neurosurgical procedure without receiving active gene therapy. uniQure has argued that repeating such a design at large scale would create substantial ethical and practical challenges once longer-term treated-patient data had already suggested a disease-modifying effect.
The U.S. Phase 1/2 study originally enrolled 26 participants, including high-dose, low-dose and sham-control groups, while the European open-label study enrolled another 13 patients. Additional cohorts subsequently examined immunosuppression strategies and high-dose treatment in patients with lower baseline striatal volume. For the pivotal three-year analysis, the company combined trial information with matched patients from Enroll-HD to estimate how similarly affected untreated patients would ordinarily be expected to progress.
This is not the same evidentiary architecture used for a conventional Phase 3 drug approval, which is why accelerated approval rather than an ordinary full approval pathway is so important. A confirmatory study would remain necessary if AMT-130 receives accelerated approval, and uniQure has been discussing a design using standard-of-care concurrent controls rather than another sham-surgery group.
How does AMT-130 attempt to slow Huntington’s disease?
Huntington’s disease results from an expanded CAG repeat within the HTT gene. The mutation causes production of an abnormal form of huntingtin protein and particularly toxic protein fragments that progressively damage neurons, eventually producing movement abnormalities, cognitive decline, behavioral changes and loss of independence.
AMT-130 uses an adeno-associated viral vector together with uniQure’s miQURE gene-silencing technology to deliver a microRNA designed to reduce expression of the huntingtin gene and toxic exon 1 protein fragment. Because the genetic vector is delivered directly into the brain, the goal is to create sustained huntingtin lowering after one procedure rather than requiring frequent systemic administration.
That one-time design creates both the attraction and the risk. A durable intervention could potentially provide years of biological activity without repeated dosing, but the treatment cannot simply be stopped and removed if an unexpected long-term problem emerges. Regulatory scrutiny therefore extends beyond short-term efficacy to neurosurgical safety, vector behavior, immune responses and durability.
How many patients have actually received AMT-130?
The overall development program remains small compared with trials supporting most mass-market medicines. The U.S. randomized trial enrolled 26 participants, the European study enrolled 13, an additional cohort included 12 patients receiving gene therapy with immunosuppression, and another U.S. cohort enrolled six high-dose patients with lower striatal volumes.
That small population is one of the most important caveats surrounding the BLA. Huntington’s disease itself is rare, and invasive intracranial gene therapy is not a treatment that can be evaluated casually in thousands of volunteers. Even so, approval would potentially expose a substantially broader patient population to the therapy, making the FDA’s judgment about the strength and generalizability of the evidence particularly important.
uniQure estimates approximately 75,000 people have Huntington’s disease across the United States, European Union and United Kingdom, with many more carrying the inherited mutation and therefore at risk of developing disease.
What happens during an AMT-130 treatment procedure?
AMT-130 is not an ordinary injection or infusion. Patients undergo targeted MRI-guided convection-enhanced stereotactic neurosurgical administration intended to place the vector directly into specific areas of the striatum. The approach aims to achieve sufficient distribution through brain regions heavily affected by Huntington’s pathology while limiting unnecessary systemic exposure.
Procedure-related adverse events have therefore always been an important component of the safety evaluation. uniQure has reported that the therapy was generally well tolerated across evaluated doses and that many of the most common adverse events were related to the administration procedure itself rather than a newly emerging toxicity attributable directly to the gene-therapy construct. Longer follow-up remains essential because one-time gene therapy is intended to produce persistent biological effects.
Why is the upcoming four-year dataset especially important?
uniQure expects to present a four-year analysis of its ongoing Phase 1/2 program before the end of the third quarter. That dataset arrives while the regulatory submissions are moving through initial review, giving both investors and regulators another opportunity to examine whether the apparent slowing of progression persists as follow-up becomes longer.
Durability is particularly important in Huntington’s disease because progression unfolds over years rather than weeks. A treatment that creates an impressive separation at three years but gradually loses that advantage would have a different clinical value from one that preserves function over substantially longer periods. Additional follow-up can also reveal late adverse events that shorter studies are poorly equipped to detect.
What should the Huntington’s disease community watch next?
The immediate milestone is whether the FDA formally accepts the BLA for filing after its initial review and whether uniQure receives the Priority Review it has requested. Submission itself does not mean the agency has determined that the application contains sufficient evidence for approval. The FDA could request additional information, decline to file the application or ultimately conclude that the external-control evidence is not sufficiently robust.
If the application advances, the debate will become one of the most consequential rare-disease regulatory decisions of the coming year. A positive outcome could produce the first approved treatment aimed at slowing Huntington’s disease progression and validate a regulatory pathway built around small gene-therapy cohorts plus rigorously matched natural-history controls. A negative decision would reinforce how high the evidence threshold remains even when the disease is devastating, the biology is clear and conventional placebo-controlled development is unusually difficult.
